A comparison of hybrid chemotherapy versus hybrid chemotherapy and autotransplant in poor prognosis Hodgkin's disease

Submission date	Recruitment status No longer recruiting	Prospectively registered	
19/08/2002		☐ Protocol	
Registration date	Overall study status	Statistical analysis plan	
19/08/2002	Completed	[X] Results	
Last Edited	Condition category	Individual participant data	
13/06/2014	Cancer		

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

Protocol serial number SNLG HDIII

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Lymphoma (Hodgkin's)

Interventions

All patients receive three 28-day cycles of PVACE-BOP (chlorambucil, procarbazine, etoposide, vinblastine, adriamycin, bleomycin and prednisolone), together with co-trimoxazole every 3 weeks for the duration of treatment.

Patients who achieve at least a partial remission are randomised to one of two treatment regimens:

- 1. Regimen A: Radiotherapy, 30 Gy in 3 weeks to initially bulky sites or residual areas of disease, followed by two further cycles of PVACE-BOP
- 2. Regimen B: Radiotherapy, 30 Gy in 3 weeks to initially bulky sites or residual areas of disease, followed by intensive chemotherapy with melphan and etoposide plus autologous bone marrow transplantation.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s))

Not provided at time of registration

Completion date

31/12/2004

Eligibility

Key inclusion criteria

- 1. Histological diagnosis of Hodgkin's disease
- 2. Prognostic index of at least 0.5
- 3. Aged under 60
- 4. No prior chemotherapy or radiotherapy
- 5. No known significant heart, lung or renal disease
- 6. No co-existing malignancies apart from localised skin lesions

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/2001

Date of final enrolment

31/12/2004

Locations

Countries of recruitment

United Kingdom

England

Study participating centre UKCCCR Register Co-ordinator

London United Kingdom NW1 2DA

Sponsor information

Organisation

UK Co-ordinating Committee for Cancer Research (UKCCCR)

ROR

https://ror.org/054225q67

Funder(s)

Funder type

Not defined

Funder Name

Not provided at time of registration

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created Date added	d Peer reviewed?	Patient-facing?
Results article	results	01/04/2002	Yes	No
Participant information sheet	Participant information sheet	11/11/2025 11/11/202	5 No	Yes